AbbVie Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending December 30, 2019 was $28.4 Billion (a 2215.97% increase compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) decreased by -988.03%
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $26.2 Billion (a 712.85% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2018 was $3.23 Billion (a -161550.0% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2017 was $-2 Million (a -100.04% decrease from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending December 30, 2019 was $26.2 Billion (a -1156.22% decrease compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) increased by 37939.13% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$26.2 Billion $-2.49 Billion $-266 Million $69 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of AbbVie Inc.

Most recent Repayment/Issuance of Debt (Net)of ABBV including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of AbbVie Inc.

AbbVie Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $28,417.0 $1,227.0 $-197.0 $-3,200.0 $26,247.0
2018 $-315.0 $3,446.0 $138.0 $-40.0 $3,229.0
2017 $-407.0 $395.0 $-7.0 $17.0 $-2.0
2016 $235.0 $-495.0 $5,860.0 $-6.0 $5,594.0
2015 $-357.0 $761.0 $16,075.0 $144.0 $16,623.0
2014 $107.0 $50.0 $248.0 $-410.0 $-5.0
2013 $2.0 $1.0 $-3.0 $-601.0 $-601.0
2012 $15,586.0 $15,586.0
2011 $-10.41 $-2.92 $13.27 $-21.03
2010 $-32.08
2009 $-34.76 $-34.77

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.